Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma

References

• National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2005. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
   Google Scholar
• Chartbook on Cardiovascular, Lung, and Blood Diseases, 2007. Available at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm [Last accessed 16 February 2008]
   Google Scholar
• Canonica GW. Treating asthma as an inflammatory disease. Chest 2006;130:21-8S
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htm [Last accessed 16 April 2008]
   Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, updated 2008. Available at: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60 [Last accessed 30 August 2009]
   Google Scholar
• Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-95
   PubMed Web of Science ®Google Scholar
• Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996;275:931-6
   Google Scholar
• Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-22
   PubMed Web of Science ®Google Scholar
• Asmanex® Twisthaler® (mometasone furoate). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2008
   Google Scholar
• Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-14
   PubMed Web of Science ®Google Scholar
• West S, King V, Carey T, et al. Systems to rate the strength of scientific evidence. Evidence Report/Technology Assessment No. 47. AHRQ Publication No. 02-E016. Rockville, MD: Agency for Healthcare Research and Quality; 2002 April
   Google Scholar
• Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch 1998;48:956-60
   PubMed Web of Science ®Google Scholar
• Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-36
   PubMed Web of Science ®Google Scholar
• Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339-54
   PubMed Web of Science ®Google Scholar
• Karpel JP. An easy-to-use dry-powder inhaler. Adv Ther 2000;17:282-6
   PubMed Web of Science ®Google Scholar
• Yang TT, Li S, Wyka B, et al. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001;14:487-94
   PubMedGoogle Scholar
• Skoner D, Gentile D. Children with mild asthma achieve peak inspiratory flow rates that allow adequate delivery of mometasone furoate from the Twisthaler® dry powder inhaler [Abstract]. Ann Allergy Asthma Immunol 2008;100, Supplement 1:A28
   Google Scholar
• D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005;21:1281-9
   PubMed Web of Science ®Google Scholar
• Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-40
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-18
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray JJ, et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-72
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999;93:603-12
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-60
   PubMed Web of Science ®Google Scholar
• Affrime MB, Kosoglou T, Thonoor CM, et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000;118:1538-46
   PubMed Web of Science ®Google Scholar
• Skoner D, Berger WE. Mometasone furoate is effective in children with asthma: Supporting evidence from clinical trials [Abstract]. Am J Respir Crit Care Med 2008;177:A710
   Google Scholar
• Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-80
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Baena-Cagnani CE, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatr Asthma, Allergy Immunol 2007;20:67-81
   Google Scholar
• Noonan M, Leflein J, Corren J, Staudinger H. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone diproprionate in children with persistent asthma. BMC Pediatrics 2009;Jul 13;9:43
   Google Scholar
• Data on file C97-380. Whitehouse Station, NJ: Merck & Co., Inc., 2008
   Google Scholar
• Skoner D, Gentile D, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy Asthma Proc 2010;31:10-19
   PubMed Web of Science ®Google Scholar
• Skoner D, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma [Abstract]. Am J Respir Crit Care Med 2003;167:A272
   Google Scholar
• National Asthma Education and Prevention Program. Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics 2002. Quick Reference. Bethesda MD: National Heart, Lung, and Blood Institute; 2002. Report No.: NIH Publication No. 02-5075
   Google Scholar